NEW YORK (GenomeWeb) – Helomics has signed an agreement to act as the clinical laboratory for Ariel Precision Medicine's PancreasDx pancreatic disease assay, the Pittsburgh-based companies announced today.
The assay is based on Ariel's Smart-MD bioinformatics platform, which combines a patient's symptoms and clinical history with next-generation sequencing data to create a profile that is then compared to multiple complex disease databases. The resulting data can be used to better understand a patient's condition and guide treatment decisions.
Specific terms of the service agreement were not disclosed.
"By leveraging Helomics' sophisticated CLIA laboratory and clinical grade NGS platform, we will be able to further accelerate the commercialization of our genomics panels for early detection and long-term management of chronic diseases such as pancreatitis," Ariel President and CEO Jessica Gibson said in a statement. "We look forward to expanding our scientific and commercial activities with Helomics as we work to leverage Pittsburgh's rich technology, professional expertise, and cutting-edge science to advance life sciences and healthcare technology in the region."